Welcome to our dedicated page for Evotec Se SEC filings (Ticker: EVOTF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. drug discovery solutions are provided in form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of innovative drug candidates and consulting arrangements. the company operates worldwide and has leading scientific experts, state-of-the-art technologies as well as key therapeutic expertise in the areas of neuroscience, pain, metabolic diseases, oncology, inflammation and infectious diseases. by leveraging this expertise, evotec intends to develop best-in-class and first-in-class differentiated therapeutics on its systematic, unbiased and comprehensive infrastructure. evotec has long-term discovery alliances with partners including bayer, boehringer ingelheim, chdi, genentech, janssen pharmaceuEvotec launched “Horizon”, the next phase of its multi‑year transformation, introducing a new operating model across operations, science and commercial execution. The company plans to streamline its global footprint to 10 sites and adjust its workforce by up to 800 positions over the next two years.
Structural Horizon measures are expected to deliver approximately €75 million run‑rate cost savings by the end of 2027, against total cash restructuring charges of about €100 million over 2026–2028, plus non‑cash impairments. Evotec enters 2026 with around €60 million annualized cost savings already realized in 2025.
Preliminary unaudited 2025 figures indicate group revenues of about €788 million and adjusted Group EBITDA of roughly €41 million, within prior guidance. For 2026, Evotec guides to group revenues of approximately €700–780 million and adjusted Group EBITDA of about €0–40 million.
The Just – Evotec Biologics segment is expected to post around €259 million revenues, up 40% year on year, and about €53 million adjusted EBITDA, while the Discovery & Preclinical Development segment is expected at roughly €529 million revenues, down 13%, with adjusted EBITDA of about -€12 million.
For 2026–2030, Evotec’s framework targets group revenues above €1 billion (8–12% CAGR) and an adjusted EBITDA margin reaching 20% by 2028 and exceeding that level by 2030.
Novo Holdings A/S now reports no ownership in Evotec SE. In this amended Schedule 13G/A, the Danish investment firm states it beneficially owns 0 ordinary shares of Evotec SE, representing 0.0% of the class, as of 12/31/2025.
The filing shows Novo Holdings has no sole or shared voting power and no sole or shared dispositive power over any Evotec shares. It confirms that Novo Holdings’ holdings are now 5 percent or less of the class, meaning it is no longer a significant beneficial owner under U.S. disclosure rules.